PAVM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PAVmed Inc. is not a good buy for a beginner investor with a long-term strategy at this time. The technical indicators are bearish, the financial performance is significantly weak, and there are no strong positive catalysts to suggest a reversal in the near term. Additionally, the lack of recent trading signals and negative stock trend projections further support a cautious approach.
The technical indicators are bearish. The MACD is negatively expanding, the RSI is neutral at 22.372, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pivot at 9.707 and S1 at 9.107. The pre-market price of 8.83 is approaching S2 at 8.737, indicating further downside risk.
Lucid Diagnostics, a subsidiary of PAVmed, reported a 25.5% revenue growth in Q4 2025 and secured a contract with the U.S. Department of Veterans Affairs to enhance EsoGuard's accessibility. The company is also working on expanding its relationship with the VA and securing Medicare coverage in 2026.
PAVmed announced a 1-for-30 reverse stock split to meet listing requirements, which often signals financial instability. The stock has a 70% chance of declining by -5.3% in the next day, -5.22% in the next week, and -7.45% in the next month. The upcoming Q4 2023 earnings report is expected to show a significant year-over-year decline in EPS, with a consensus estimate of -$4.50.
The company's financial performance is significantly weak. In Q3 2025, revenue dropped by -99.50% YoY to $5,000, net income declined by -109.84% YoY to -$6,328,000, and EPS fell by -120.38% YoY to -$8.81. While gross margin improved to -1000, this is still a negative figure, indicating poor profitability.
No recent analyst ratings or price target changes are available for PAVmed Inc.
